This content is from: Premium

Say What!? The Bill Ackman Acolyte, the Prince Who Came to Dinner

“Another kick in the teeth.” Troy Gayeski of SkyBridge Capital, commenting on the 30 percent drop in the price of Irish pharmaceutical maker Shire after U.S. drug company AbbVie confirmed it was cancelling a plan to acquire Shire for $54 billion. Hedge funds including Paulson & Co. had had billions

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content